Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection

Koen Vandyck1 and Jerome Deval2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the COVID-19 pandemic. The coronavirus 3-chymotrypsin-like protease (3CLpro) controls virus replication and is therefore considered a major target and promising opportunity for rational-based antiviral discovery with direct acting agents. Here we review first-generation SARS-CoV-2 3CLpro inhibitors PF-07304814, GC-376, and CDI-45205 that are being delivered either by injection or inhalation due to their low intrinsic oral bioavailability. In addition, PF-07321332 is now emerging as a promising second-generation clinical candidate for oral delivery. A key challenge to the development of novel 3CLpro inhibitors is the poor understanding of the predictive value of in vitro potency toward clinical efficacy, an issue complicated by the involvement of host proteases in virus entry. Further preclinical and clinical validation will be key to establishing 3CLpro inhibitors as a bona fide class for future SARS-CoV-2 therapeutics for both hospitalized and outpatient populations.

Addresses
1 Aligos Belgium BV, Leuven, Belgium
2 Aligos Therapeutics, Inc., South San Francisco, USA

Corresponding authors: Vandyck, Koen (k.vandyck@aligos.com), Deval, Jerome (j.deval@aligos.com)

Introduction
COVID-19 is a respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although most infected individuals are either asymptomatic or experience self-limiting symptoms similar to the common cold, clinical cases of severe COVID-19 require hospitalization and intensive care due to pneumonia and extra-pulmonary manifestations [1,2]. The anti-inflammatory corticosteroid dexamethasone, and nucleotide analog remdesivir are considered the standards of care for the treatment of severe COVID-19 in hospitalized patients needing supplemental oxygen (https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/). However, these molecules are not suitable for patients in the early stage of SARS-CoV-2 infection, in outpatient settings, or as prophylaxis. SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus that belongs to the β-coronavirus genus of the Coronavirus family [3]. The main viral protease, 3CLpro, is a cysteine protease with distinctive substrate preference for glutamine at the P1 site (Leu-Gln/(Ser,Ala,Gly)) [4]. Because of its key role in viral replication, 3CLpro is considered a major target for antiviral drug discovery. Intense research and development are currently ongoing to evaluate 3CLpro inhibitors as potential treatments for COVID-19.

Origin and status of first-generation 3CLpro inhibitors
The urgent need for COVID-19 treatments triggered rapid repurposing of protease inhibitors previously developed for other viral indications. FDA-approved HIV protease inhibitors do not provide any benefit for COVID-19 patients [5]. The most interesting subgroup of protease inhibitors are peptidomimetics previously designed to inhibit 3C-like or 3CL-like proteases. These molecules contain a P1-glutamine surrogate, like those designed for the discovery of the rhinovirus 3Cpro inhibitor rupintrivir [6]. While rupintrivir itself did not display significant activity against SARS-CoV-2 3CLpro [7], peptidomimetics previously described for other coronaviruses were expected to have broad activity across most coronaviruses as their substrate cleavage sites are highly conserved (for review: Ref. [8]). Unsurprisingly, some peptidomimetic compounds active against MERS and SARS-CoV-1 are also active against SARS-CoV-2. PF-00835231 was developed more than 15 years ago against SARS-CoV-1 (patent WO2005113580) and recently showed high in vitro potency against SARS-CoV-2 (Figure 1) [9,10**]. Currently its phosphate prodrug PF-07304814 is being evaluated in a Phase 1b clinical trial in hospitalized patients with COVID-19; safety and efficacy results are expected around mid-2021 (ClinicalTrials.gov Identifier NCT04535167). The peptidomimetic compound GC-376 is a broad-spectrum inhibitor of 3C and 3CL-like proteases of picornaviruses, noroviruses and coronaviruses (Figure 1) [11*]. The compound has been licensed to Anivive, a company focusing on Companion animal veterinary medicine, to treat feline
infectious peritonitis caused by a feline coronavirus [11,12–14]. GC-376 was confirmed to also block SARS-CoV-2 [15,16], providing a scientific rationale for a pre-IND submission for the treatment COVID-19 (https://www.prnewswire.com/news-releases/anivive-repurposes-veterinary-drug-gc-376-for-covid-19-and-submits-pre-ind-to-fda-301065619.html). GC-376 is a sodium bisulfite prodrug of the aldehyde GC-373. Bisulfite adducts increase chemical stability and/or aqueous solubility of aldehydes. GC-373 has been described as a potent cathepsin B inhibitor [17], and its prodrug GC-376 has been described as a potent cathepsin L inhibitor [7]. The low target selectivity of GC-376 and many other 3CLpro inhibitors could present a challenge for clinical development. In particular, 3CLpro inhibitors that lack selectivity toward cathepsin L may potentially have counter-effecti ve side effects by dampen ing the immune response against SARS-CoV-2 [18]. The broad spectrum of virus protease inhibition previously reported for GC-376 combined with the cathepsin L inhibition effect suggest its activity may extend to other human proteases. CDI-45205 (undisclosed structure) is the latest compound to advance into late preclinical stage (https://www.cocrystalpharma.com/news/press-releases/detail/105/cocrystal-pharma-selects-lead-compound-for-further). It was selected by Cocrystal Pharma at the end of 2020 from the broad-spectrum protease inhibitors discovered by Kansas State University Research Foundation, which demonstrated in vitro and in vivo activity in animal models against MERS and in vitro activity against SARS-CoV-2 [19].

**Routes of administration of first-generation inhibitors and emergence of a second-generation oral drug candidate**

Although SARS-CoV-2 infects mainly the respiratory tract (pharynx, trachea, lungs) at the early stages of the self-limiting infection, a broader organotropism has been reported in more severe and advanced cases of illness [20–22]. In addition to the principal target organs of virus replication, several other factors need to be considered when optimizing the route of administration of a 3CLpro inhibitor, including the timing of intervention relative to SARS-CoV-2 infection, COVID-19 disease stage, and bioavailability of the antiviral agent (Figure 2). The nucleotide analog remdesivir is approved in the United States for the intravenous infusion treatment of hospitalized patients only; therefore, the need for easier administration of a direct acting agent in early stage non-hospitalized patients remains high, as is the need for pre-exposure or post-exposure prophylaxis options. In this context oral delivery would be ideal for use in the early stages of disease management or in a pre-exposure or post-exposure setting. The intrinsically low oral bioavailability of the first-generation 3CLpro inhibitors has been a challenge to their clinical development. Both PF-00835231 and GC-376 have low oral bioavailability in rats of 1.4% and 3%, respectively ([10**], Patent WO2013049382). The low oral bioavailability and short predicted half-life in human of PF-00835231 was improved with a highly soluble prodrug PF-07304814 that allowed continuous infusion using a minimal dosing volume to reach estimated minimal efficacious levels in clinical trials [10**]. The planned route of administration for CDI-45205 is injection or inhalation for potential use as both a therapeutic and prophylactic (https://www.cocrystalpharma.com/news/press-releases/detail/105/cocrystal-pharma-selects-lead-compound-for-further). Other less advanced 3CLpro inhibitors have also been administered by subcutaneous or intraperitoneal injection to circumvent the issue of low oral bioavailability. For example, a SARS-CoV-2 3CLpro inhibitor (designated 11a) had a bioavailability of 88% when dosed by intraperitoneal route in mice [23]. Separate reports that 3CLprotease human rhinovirus peptidomimetic inhibitors have oral bioavailability greater than 20% in rodents and other nonclinical species suggest that this chemical class is potentially amenable to oral administration [6,24,25].

At the time of the publishing of this manuscript, Pfizer announced the launch of a Phase 1 clinical study (NCT04756531) with the second-generation orally available 3CLpro inhibitor PF-07321332 (https://cen.acs.org/acs-news/acs-meeting-news/Pfizer-unveils-oral-SARS-
Considerations on the route of administration of a 3CLpro inhibitor. To be used in prophylaxis or early stage SARS-CoV-2 infection in outpatient setting, oral administration of a 3CLpro inhibitor is preferred over inhalation and subcutaneous (SC) injection. For more severe cases of COVID-19 requiring hospitalization, intravenous (IV) administration is preferred over oral and inhalation.

CoV/99/13). PF-07321332 contains a nitrile warhead and was optimized for oral delivery by the reduction of the number of H-bond donors and application of a trifluoroacetetyl capping group in P4 (Figure 1).

**Pitfalls and challenges in assessing the preclinical antiviral potency of 3CLpro inhibitors**

The need to discover and develop second-generation 3CLpro inhibitors with improved potency and/or bioavailability is high. In addition, 3CLpro inhibitors commonly target host proteases, which presents a potential liability for unexpected side effects. Therefore, increased target specificity might be critical for future development. However, preclinical evaluation of antiviral potency remains challenging for this class of compounds. Conflicting results of protease inhibitor testing emerged during the early months of the COVID-19 pandemic due to non-standardized assay conditions among research laboratories. For example, the three drugs shikonin, disulfiram, and ebselen previously approved for other indications were reported to inhibit SARS-CoV-2 3CLpro in enzymatic and antiviral assays [26**]. However, enzyme inhibition was only achieved in the absence of physiologically relevant reducing agents, and the reported antiviral effect in cells infected with SARS-CoV-2 could not be reproduced and was therefore suspected to be an indirect consequence of cell death [15*].

Similar lack of reproducibility in SARS-CoV-2 inhibition due to cytoxicity artefacts have been reported with HIV protease inhibitors nelfinavir and atazanavir [27]. These issues highlight the importance of proper assay conditions and controls to ensure correct interpretation of in vitro protease inhibitor testing results. Additional challenges in assessing 3CLpro inhibition potency in infected cells arose from the role of host proteases in virus entry. SARS-CoV-2 uses human ACE2 as its entry receptor and human proteases as entry activators including cell surface transmembrane protease/serine (TMPRSS) proteases, furin, cathepsins, plasmin, elastase, and trypsin (for reviews: Refs. [28,29]). Although the relevance of individual host proteases at the site of infection remains subject to debate, the consensus is that SARS-CoV-2 enters cells mainly through direct membrane fusion by TMPRSS2 protease activation [30**]. In addition to the TMPRSS2-facilitated direct entry from the cell membrane, SARS-CoV-2 can also enter cells through the endosomal pathway, where spike proteins are proteolytically activated by the lysosomal cathepsin L and/or B proteases [31]. Therefore, optimizing and developing protease inhibitors for SARS-CoV-2 face distinctive challenges due to the multiple host proteases and their level of redundancy for viral entry. In vitro, the antiviral activity of protease inhibitors largely depends on the mechanism of SARS-CoV-2 cellular entry and is driven by the levels of host protease expression in the cells. For example, the rhinovirus inhibitor rupintrivir and the cathepsin inhibitor K11777 block SARS-CoV-2 replication in A549 lung epithelial cells, but their antiviral effect was greatly diminished when TMPRSS2 was overexpressed [32*]. These examples highlight the difficulty of establishing physiologically relevant antiviral assays due to the influence of host protease expression on the mechanism of virus entry. For these reasons, cellular assays risk overpredicting the true potential antiviral effect of broad-spectrum 3CLpro inhibitors that also target cathepsin L and/or other host proteases involved in virus entry [7].

Consequently, it is imperative to validate the protease target (host and/or viral) and the antiviral approach with animal models of virus infection. GC-376 is probably the most studied protease inhibitor in animal models among the current candidates for SARS-CoV-2 treatment. GC-376 administered subcutaneously twice daily resulted in partial to full recovery in laboratory and client-owned cats infected
with feline coronavirus [11*,14]. In a mouse model of SARS-CoV-2 infection, intranasal and combined intranasal + intramuscular treatment with GC-376 only achieved marginal reduction in viral load [33]. The antiviral effect of GC-376 was improved when combined with GS441524, the parent nucleoside of the remdesivir produg. The lack of clear antiviral effect of GC-376 monotherapy in this study might be due to insufficient drug exposure caused by its suboptimal pharmacokinetic properties. Very recently, more convincing animal model efficacy data has emerged with other 3CLpro inhibitors. In a mouse model of SARS-CoV-1 infection, PF-00835231 significantly reduced lung viral titers up to two days post-infection, also alleviated signs of disease such as weight loss and lung pathology [10**]. Other molecules derived from beceprevir or telaprevir also demonstrated antiviral activity in a mouse model of SARS-CoV-2 infection [34*]. Finally, ALG-097111 was reported as a potent and highly selective 3CLpro inhibitor with antiviral activity in a SARS-CoV-2 hamster model [35].

Conclusion

The two main classes of direct acting agents for the treatment of SARS-CoV-2 infection are polymerase (nsp12) and protease (3CLpro) inhibitors. The nucleotide analog remdesivir is already approved as a polymerase inhibitor for hospitalized COVID-19 patients, and MK-4482/EIDD-2801, also a polymerase inhibitor, is efficacious in animal models and is currently being evaluated in the clinic [36–38]. In comparison, the most advanced 3CLpro inhibitor PF-07304814 is still in early stage clinical trial evaluation as an intravenous infusion treatment and has not yet been reported to demonstrate antiviral activity in humans. The emergence of the orally bioavailable clinical candidate PF-07321332 will help to address early stage non-hospitalized patients as well as potential prophylaxis settings. Although more proof-of-concept work is needed to fully validate 3CLpro inhibitors, this class of compounds provides a promising avenue to treat coronavirus infections either as monotherapies or in combination with other antiviral agents.

Conflict of interest statement

The authors of this manuscript have the following competing interests: JD is current employee of Aligos Therapeutics, Inc., and KV is current employee of Aligos Belgium BV.

Acknowledgements

We thank Julian Symons and Peggy Korn for their careful editorial review of the manuscript.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- ** of outstanding interest

1. Harapan H, Itoh N, Yufika A, Winardi W, Kearn S, Te H, Megawati D, Hayati Z, Wagner AL, Mustafiir M. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health 2020, 13:667–673.
2. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC: Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020, 324:782–793.
3. Coronavirus Study Group of the International Committee on Taxonomy of Viruses: The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020, 5:536–544.
4. Fan K, Ma L, Han X, Liang H, Wei P, Liu Y, Lai L: The substrate specificity of SARS coronavirus 3C-like protease. Biochem Biophys Res Commun 2005, 329:934–940.
5. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M et al.: A trial of Lopinavir-Ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020, 382:1787–1799.
6. Patrick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ 3rd, Zalman LS, Burns-Naas LA, Tran JQ: In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 2005, 49:2267–2275.
7. Liu C, Boland S, Scholle M, Bardiot D, Marchand A, Chaltin P, Blatt L, Beigelman L, Symons J, Raboison P et al.: Dual inhibition of SARS-CoV-2 and human rhinovirus protease inhibitors in clinical development. Antiviral Res 2021, 187:105020 http://dx.doi.org/10.1016/j.antiviral.2021.105020.
8. Ulrich S, Nitsche C: The SARS-CoV-2 main protease as drug target. Biorg Med Chem Lett 2020, 30:127377.
9. Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, von Brunn A, Lysens P, Lanko K, Neyts J et al.: Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. J Med Chem 2020, 63:4562–4578.
10. Boras B, Jones RM, Anson BJ, Aresnson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H et al.: Discovery of a novel inhibitor of coronavirus 3C protease as a clinical candidate for the potential treatment of COVID-19. bioRxiv 2021, 3.
11. Kim Y, Lovell S, Tiew KC, Mandadapu SR, Alliston KR, Battaile KP, Groutas WC, Chang KO: Broad-spectrum antivirals against SARS-CoV-2-like coronaviruses: noroviruses, coronaviruses, and picornaviruses. J Virol 2012, 86:11754–11762.
12. First report of the broad in vitro antiviral activity of GC-376.
13. Takahashi D, Kim Y, Lovell S, Prakash O, Groutas WC, Chang KO: Structural and inhibitor studies of norovirus 3C-like proteases. Virus Res 2013, 178:437–444.
14. Kim Y, Liu H, Galasiti Kankanamalage AC, Weerasekara S, Hua DH, Groutas WC, Chang KO, Pedersen NC: Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog 2016, 12:e1005531.
15. Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, Bannasch M, Meadows JM, Chang KO: Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J Feline Med Surg 2018, 20:378–392.
16. Gurard-Levin ZA, Liu C, Jekle A, Jaisinghani R, Ren S, Vandyck K, Jochmans D, Lysens P, Neyts J, Blatt LM et al.: Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry. Antiviral Res 2020, 182:104924.

Indicates the importance of reducing agents in 3CLpro assay conditions for inhibitor testing, as well as cytotoxicity as a false positive readout for
antiviral effect. Contrary to previous reports, this study reveals that shikonin is not a promising 3CLpro inhibitor.

16. Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, Zhang X, Tarbet B, Marty MT, Chen Y, Wang J: Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res 2020, 30:678-692.

17. Swisher LZ, Prior AM, Gunaratna MJ, Shishido S, Madiyar F, Nguyen TA, Hua DH, Li J: Quantitative electrochemical detection of cathepsin B activity in breast cancer cell lysates using carbon nanotube nanoelectrode arrays toward identification of cancer formation. Nanomedicine 2015, 11:1695-1704.

18. Baranov MV, Bianchi F, van den Bogaart G: The PIKfyve inhibitor apilimod: a double-edged sword against COVID-19. Cells 2020, 10.

19. Rathnayake AD, Zheng J, Kim Y, Perera KD, Mackin S, Meyerholz DK, Kashipathy MM, Battaile KP, Lovell S, Perlman S et al.: 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice. Sci Transl Med 2020, 12.

20. Kruger J, Gross R, Conzelmann C, Muller JA, Koepke L, Sparrer KJ, Weil T, Schutz D, Seufferlein T, Barth TF et al.: Drug inhibition of SARS-CoV-2 replication in human pluripotent stem cell-derived intestinal organoids. Cell Mol Gastroenterol Hepatol 2021, 11:935-948.

21. Tryptstein W, Van Cleemput J, Snippenberg VW, Gerlo S, Vandekerckhove L: On the whereabouts of SARS-CoV-2 in the human body: a systematic review. PLoS Pathog 2020, 16: e1009037.

22. Zhang Y, Geng X, Tan Y, Li Q, Xu C, Xu J, Hao L, Zeng Z, Luo X, Liu F, Wang H: New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed Pharmacother 2020, 127:110185.

23. Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F et al.: Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 2020, 368:1331-1335.

24. Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T et al.: Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridine-containing peptidomimetics. J Med Chem 2003, 46:4572-4585.

25. Kim Y, Kankamalamage AC, Damalanka VC, Weerawarna PM, Goutas WG, Chang KO: Potent inhibition of enterovirus D68 and human rhinoviruses by dipeptidyl aldehydes and alpha-ketoamides. Antiviral Res 2016, 125:84-91.

26. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C et al.: Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020, 582:289-293.

First report of the crystal structure of SARS-CoV-2 main protease 3CLpro, together with Dai et al. [23] and Zhang et al. [9].

27. Hattori SI, Higashit-Kuwata N, Hayashi H, Allu SR, Raghavaiah J, Bulut H, Das D, Anson BJ, Lendy EK, Takamatsu Y et al.: A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun 2021, 12:668.

28. Millet J, Whittaker GR: Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res 2015, 202:120-134.

29. Luan B, Huynh T, Cheng X, Lan G, Wang HR: Targeting proteases for treating COVID-19. J Proteome Res 2020, 19:4316-4326.

30. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Hentler T, Ehrens S, Schiergens TS, Hentler G, Wu NH, Nitsche A et al.: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020, 181:271-280.e278.

This study reveals the importance of TMPRSS2 in SARS-CoV-2 entry.

31. Pissiar A, Mitrovic A, Sabotic J, Pecar Fonovic U, Perisic Narut M, Jakos T, Senior E, Kos J: The role of cysteine peptidases in coronavirus cell entry and replication: the therapeutic potential of cathepsin inhibitors. PLoS Pathog 2020, 16: e1009013.

32. Steuten K, Kim H, Widen J, Babin B, Onguka O, Lovell S, Bolgi O, Cerkkan B, Cortese M, Muir R et al.: Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19. ACS Infect Dis 2021, aicsf000815.

First demonstration of the redundancy between cathepsin L and TMPRSS2 for in vitro viral entry.

33. Shi Y, Shuai L, Wen Z, Wang C, Yan Y, Jiao Z, Guo F, Fu ZF, Chen H, Bu Z: The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract. Emerg Microbes Infect 2021, 10:481-492 http://dx.doi.org/ 10.1080/22221751.2021.1899770.

34. Qiao J, Li YS, Zeng R, Liu FL, Luo RH, Huang C, Wang YF, Zhang J, Quan B, Chen C et al.: SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model. Science 2021, 373:1374-1378.

Important proof-of-concept demonstration of lung viral load reduction with an oral 3CLpro inhibitor in a transgenic mouse model of SARS-CoV-2 infection.

35. Vandyck K, Abdelnabi R, Gupta K, Jochmans D, Jekle D, Deval J, Miser D, Bardiot D, Foo CS, Liu C et al.: ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibiting in vivo efficacy in a Syrian Hamster model. Biochem Biophys Res Commun 2021, 555:134-139.

36. Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schafer A, Dinnon KH 3rd, Stevens LJ et al.: An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 2020, 12.

37. Zhu W, Chen CZ, Gokshor K, Xu M, Lo DC, Zheng W: RNA-dependent RNA polymerase as a target for COVID-19 drug discovery. SLAS Discov 2020, 25:1141-1151.

38. Cox RM, Wolf JD, Plummer RK: Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol 2021, 6:11-18.